ArticleJournal of translational medicine2026
SLAMF8 promotes tumor growth of gastric cancer by enhancing M2 polarization of tumor-associated macrophages.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe signaling lymphocytic activation molecule family member 8 (SLAMF8) is predominantly expressed on the surface of macrophages and participates in modulating tumor immune microenvironment. However, the role of SLAMF8 in tumor-associated macrophages (TAMs) in gastric cancer (GC) remains unclear.
methodsSLAMF8 expression and its association with patient prognosis were analyzed using various online databases. CCK-8 and EdU assays were used to assess GC cell proliferation. A xenograft tumor model was used to assess the in vivo functional role of SLAMF8.
resultsSLAMF8 expression was markedly increased and correlated with an unfavorable prognosis in GC. Additionally, SLAMF8 was primarily expressed in macrophages in GC tissues and increased in in vitro-generated-TAMs. SLAMF8 knockdown suppressed M2 polarization, whereas SLAMF8 overexpression promoted M2 polarization in in vitro-generated TAMs. SLAMF8 facilitates TAM-like polarization by coordinately inhibiting NF-κB activation and activating the JAK2/STAT3 signaling pathway. Furthermore, SLAMF8-overexpressing TAMs enhanced the growth of MKN-45 cells both in vitro and in vivo and impaired CD8 + T cell function.
conclusionsSLAMF8 promotes macrophage M2 polarization and accelerates CD8 + T cell dysfunction, thereby facilitating the progression of GC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.